- We argued that the company is a ground-floor opportunity on the regenerative medicine revolution, which is just in the early innings.
- The company is winning dozens of new customers a quarter, increasing the pool of possible regulatory approvals and the accompanying prospect of a step up in revenues.
- Already profitable and cash generating, the shares aren’t all that expensive.
It’s Still Not Too Late To Get On Board Of The BioLife Solutions Train
May 19th, 2019 · No Comments